文献速递艾滋病与性传播感染

中国西南地区接受抗逆转录病毒治疗的艾滋病病毒低水平病毒血症患者耐药突变流行率:一项横断面研究

Prevalence of drug resistance mutations in low-level viremia patients under antiretroviral therapy in Southwestern China: a cross-sectional study.
PubMed 文献 · J Antimicrob Chemother · 2025-01-01

本研究在中国西南云南省开展横断面研究,纳入接受抗逆转录病毒治疗至少6个月、血浆病毒载量50–999 copies/mL的低水平病毒血症患者,采用经验证的本土方法检测HIV-1耐药突变。共获得470条序列,耐药突变总流行率为45.7%(215/470),以非核苷类逆转录酶抑制剂相关突变为主(39.4%),结论认为该地区低水平病毒血症患者耐药突变流行率高、HIV-1基因型多样,定期耐药监测对有效临床治疗与管理至关重要。

要点

  • 低水平病毒血症患者耐药突变总流行率为45.7%(215/470),以非核苷类逆转录酶抑制剂相关突变为主(39.4%,185/470)。
  • 最常见非核苷类逆转录酶抑制剂相关突变为K103N(16.0%)、E138A(6.6%)、V179D(6.6%)和P225H(4.9%)。
  • 最常见核苷类逆转录酶抑制剂相关突变为M184V(17.0%)、D67N(3.4%)和K65R(3.0%);蛋白酶抑制剂相关突变少见,均低于1.8%。

核心结论

  • 接受抗逆转录病毒治疗的低水平病毒血症患者耐药突变流行率高,云南地区HIV-1基因型呈多样性。
  • 作者认为,低水平病毒血症期间定期进行耐药突变监测对该地区有效临床治疗与管理至关重要。

研究设计与样本

  • 横断面研究,在中国西南云南省开展。
  • 低水平病毒血症定义为接受抗逆转录病毒治疗至少6个月、血浆病毒载量50–999 copies/mL。
  • HIV-1耐药突变检测采用经验证的本土方法,共获得470条序列。

主要发现

  • 共鉴定出13种HIV-1基因型,最常见为CRF08_BC(47.5%)、CRF07_BC(22.3%)和CRF01_AE(10.0%)。
  • 耐药突变总流行率为45.7%(215/470)。
  • 非核苷类逆转录酶抑制剂、核苷类逆转录酶抑制剂和蛋白酶抑制剂相关耐药突变流行率分别为39.4%(185/470)、20.6%(97/470)和5.3%(25/470)。
  • 非核苷类逆转录酶抑制剂相关突变K101E和Y188C的流行率在不同低水平病毒血症组间差异有统计学意义。
  • 非核苷类逆转录酶抑制剂相关突变V106I、V106M、E138A和P225H、核苷类逆转录酶抑制剂相关突变K65R及蛋白酶抑制剂相关突变L33F和Q58E的流行率在不同亚型间存在显著差异。

关键数值与推荐

  • 低水平病毒血症定义:血浆病毒载量50–999 copies/mL且抗逆转录病毒治疗至少6个月。
  • 最常见非核苷类逆转录酶抑制剂相关突变:K103N(16.0%)、E138A(6.6%)、V179D(6.6%)、P225H(4.9%)。
  • 最常见核苷类逆转录酶抑制剂相关突变:M184V(17.0%)、D67N(3.4%)、K65R(3.0%)。
  • 蛋白酶抑制剂相关突变少见,发生于不足1.8%的病例。

临床怎么用

  • 作者认为,低水平病毒血症期间定期进行耐药突变监测对该地区有效临床治疗与管理至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aimed to evaluate the prevalence and characteristics of drug resistance mutations (DRMs) in patients with low-level viremia (LLV) in Southwestern China, as it has become a growing challenge in AIDS clinical practice. METHODS: This cross-sectional study was performed in Yunnan Province, Southwestern China. LLV was defined as 50-999 copies/mL of plasma viral load with antiretroviral therapy (ART) for at least 6 months. HIV-1 DRM detection used validated in-house protocol. RESULTS: A total of 470 sequences were obtained, and 13 HIV-1 genotypes were identified, among which CRF08_BC (47.5%), CRF07_BC (22.3%) and CRF01_AE (10.0%) subtypes were the most prevalent. The overall prevalence of DRMs was 45.7% (215/470), and the prevalence of DRMs to non-nucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs) and protease inhibitors (PIs) was 39.4% (185/470), 20.6% (97/470) and 5.3% (25/470), respectively. The most common NNRTI-associated mutations were K103N (16.0%), E138A (6.6%), V179D (6.6%) and P225H (4.9%), and those in NRTIs were M184V (17.0%), D67N (3.4%) and K65R (3.0%). PI-associated mutations were infrequent, occurring in less than 1.8% of cases. The prevalence of NNRTI-associated mutations (K101E and Y188C) was found to be statistically significant among various LLV groups. Additionally, significant variations were observed in the prevalence of NNRTI-associated mutations (V106I, V106M, E138A and P225H), NRTI-associated mutation (K65R) and PI-associated mutations (L33F and Q58E) across different subtypes. CONCLUSIONS: The prevalence of DRMs in ART-experienced patients with LLV was high, and HIV-1 genotypes exhibited diversity in Yunnan Province. These findings indicate that regular DRM monitoring during LLV episodes was essential for effective clinical treatment and management in this region.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Shu Y, Liu J, Yang C, et al. Prevalence of drug resistance mutations in low-level viremia patients under antiretroviral therapy in Southwestern China: a cross-sectional study. J Antimicrob Chemother. 2025. PMID: 39835338. doi:10.1093/jac/dkaf017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。